Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Sunday, 23andMe Announced Nonclinical Data Supporting The Anti-tumor Activity Of 23Me-01473 Antibody Targeting NKG2D Ligand ULBP6, At The ESMO Congress

Author: Benzinga Newsdesk | September 16, 2024 05:27am
  • 23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer.
  • Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity.
  • Phase 1 trial ongoing with first patient dosed in March 2024

Posted In: ME


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist